Is Tesamorelin FDA-Approved? What Researchers Need to Know

Tesamorelin is one of the very few peptide research compounds that also holds a formal FDA marketing authorization. Understanding what that approval covers and, crucially, what it does not cover is essential context for anyone conducting research with this compound. This guide summarizes the regulatory history, the mechanism behind the approved indication, and what published studies report about tesamorelin's effects.

The Short Answer

Yes. The FDA approved tesamorelin under the brand name Egrifta in November 2010. The approval is narrow and specific: it covers reduction of excess visceral adipose tissue in HIV-infected adults with lipodystrophy. Outside that single indication, tesamorelin does not carry FDA clearance for any use, and it is handled as a research compound in all other study contexts.

What the Approval Actually Covers

Theratechnologies developed Egrifta as a synthetic analogue of growth hormone-releasing hormone (GHRH). The FDA authorization rests on two pivotal Phase 3 trials, designated LIPO-010A and LIPO-010B, which enrolled HIV-positive adults with documented excess visceral fat associated with antiretroviral therapy. At the 26-week primary endpoint, subjects receiving tesamorelin 2 mg subcutaneously once daily showed statistically significant reductions in visceral adipose tissue measured by CT scan compared with placebo.

A second-generation formulation, Egrifta SV (the stabilized version), received FDA clearance in 2019. It replaced the original lyophilized powder with a more stable aqueous preparation that does not require refrigeration after reconstitution in the same way.

Key parameters of the approved indication:

• Approved population: HIV-infected adults with lipodystrophy
• Approved route: Subcutaneous injection, once daily at bedtime
• Approved dose in trials: 2 mg per day (research-reported figure, not a dosing recommendation)
• Primary endpoint measured: Visceral adipose tissue reduction by CT scan at 26 weeks
• Mechanism: Stimulation of pulsatile growth hormone release from pituitary somatotrophs via GHRH receptor binding

What the Approval Does Not Cover

The Egrifta approval is frequently misunderstood in research literature. The following uses fall entirely outside the FDA authorization:

• General visceral fat reduction in metabolically healthy subjects
• Anti-aging, longevity, or body recomposition applications
• Athletic performance enhancement
• Combination protocols pairing tesamorelin with ipamorelin, CJC-1295, or other secretagogues
• Any use in subjects without HIV-associated lipodystrophy

Research into these off-label areas is ongoing at academic and private lab levels, but that work treats tesamorelin as a research chemical under separate regulatory classification. The pharmaceutical approval of Egrifta applies to the Theratechnologies-manufactured product only, not to research peptide preparations sourced from third-party suppliers.

Mechanism: Why Tesamorelin Attracts Research Interest

Tesamorelin binds the GHRH receptor on pituitary somatotrophs and stimulates pulsatile release of endogenous growth hormone. This is fundamentally different from exogenous recombinant GH administration, which produces a sustained, non-pulsatile GH elevation. Because tesamorelin works upstream and preserves the natural secretory pattern, it tends to produce a more moderate IGF-1 rise than direct GH administration. That characteristic has made it useful in study designs where avoiding supraphysiologic IGF-1 is important.

For researchers comparing GHRH analogues, tesamorelin sits in a similar mechanistic space to CJC-1295, though with a much shorter half-life of approximately 26 to 38 minutes versus CJC-1295's multi-day half-life when DAC-conjugated. This distinction affects study design around dosing timing. A direct comparison of secretagogue options is covered in the tesamorelin vs ipamorelin guide.

Study-Reported Effects: A Reference Table

The following data derives from the Egrifta Phase 3 trial publications and is presented as research-reported information only. These are not dosing recommendations.

Preclinical research in rodent models has investigated tesamorelin in the context of non-alcoholic fatty liver disease, cognitive function, and metabolic syndrome. These areas lack robust human trial data and represent active research frontiers rather than established findings.

Reconstitution and Laboratory Handling

For in vitro or in vivo research use, tesamorelin requires reconstitution from lyophilized form. Accurate calculation of bacteriostatic water volume relative to vial mass is critical to maintaining intended concentration across an experimental series. Use the peptide reconstitution calculator to generate volume figures for your specific vial size before beginning work. General reconstitution technique is covered in the protocols section.

For study-reported dosage figures used in tesamorelin research, the tesamorelin dosage reference summarizes what the clinical and preclinical literature reports, including the per-day amounts used in the pivotal trials.

Researchers sourcing tesamorelin for laboratory use should prioritize suppliers that publish lot-specific certificates of analysis, including HPLC purity and mass spectrometry confirmation. The supplier reference page lists vendors that meet that standard for GHRH class peptides.

Summary

• Tesamorelin is FDA-approved under the brand name Egrifta for one indication: reducing excess visceral adipose tissue in HIV-infected adults with lipodystrophy.
• The approval covers the pharmaceutical product from Theratechnologies, not research peptide preparations.
• The mechanism is upstream GHRH receptor stimulation producing pulsatile GH release, distinct from direct GH administration.
• Phase 3 trial data shows significant visceral fat reduction at 26 weeks in the approved population, alongside modest IGF-1 elevation that reverses after discontinuation.
• Research into off-label applications, including metabolic and cognitive endpoints in healthy subjects, is ongoing but not supported by the same level of clinical evidence.
• The EU no longer holds a valid EMA marketing authorization for Egrifta as of 2016.